Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up

Elena Z. Golukhova, Marina V. Grigorian, Mariya N. Ryabinina, Naida I. Bulaeva, Seth Fortmann, Victor L. Serebruany

Research output: Contribution to journalArticle

Abstract

Background: Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality. Therefore, predicting secondary vascular occlusions represents an unmet medical need. Objective: The aim of our study was to triage clinical and laboratory predictors of major adverse clinical events (MACE) following coronary stenting. Methods: This was a prospective, case-controlled, single-center study, which included 94 consecutive patients with documented coronary disease who underwent PCI with drug-eluting stent (DES) implantation. All patients received dual antiplatelet therapy with aspirin and clopidogrel. Numerous clinical characteristics and laboratory biomarkers were assessed before stenting and were correlated with poststenting MACE over the mean follow-up of 28 months. MACE included death, nonfatal myocardial infarction, target vessel revascularisation, stroke, stent thrombosis, angina recurrence and instent restenosis. Results: Twenty-three patients experienced MACE. Independent MACE predictors after PCI with DES implantation were antecedent diabetes mellitus (RR = 0.45; 95% CI 0.20-0.97; p = 0.045), prior thrombolytic therapy (RR = 0.42; 95% CI 0.27-0.83; p = 0.039), baseline plasminogen activator inhibitor-1 (PAI-1; p = 0.008) and plasma von Willebrand factor (vWF) activity (p = 0.007). Other clinical characteristics and laboratory indices showed no correlation with MACE. Conclusions: Background diabetes mellitus, prior thrombolytic therapy, PAI-1 and vWF prestenting activity may be useful for MACE prediction over 28 months of follow-up.

Original languageEnglish (US)
Pages (from-to)176-181
Number of pages6
JournalCardiology
Volume132
Issue number3
DOIs
StatePublished - Oct 9 2015

Fingerprint

Plasminogen Activator Inhibitor 1
Percutaneous Coronary Intervention
Drug-Eluting Stents
clopidogrel
Thrombolytic Therapy
von Willebrand Factor
Stents
Diabetes Mellitus
Triage
Aspirin
Coronary Disease
Blood Vessels
Thrombosis
Biomarkers
Stroke
Myocardial Infarction
Pharmacology
Morbidity
Recurrence
Mortality

Keywords

  • Coronary artery stenting
  • Dual antiplatelet therapy
  • Plasminogen activator inhibitor-1
  • Platelet aggregation
  • Stent restenosis
  • Stent thrombosis
  • von Willebrand factor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Golukhova, E. Z., Grigorian, M. V., Ryabinina, M. N., Bulaeva, N. I., Fortmann, S., & Serebruany, V. L. (2015). Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. Cardiology, 132(3), 176-181. https://doi.org/10.1159/000435909

Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. / Golukhova, Elena Z.; Grigorian, Marina V.; Ryabinina, Mariya N.; Bulaeva, Naida I.; Fortmann, Seth; Serebruany, Victor L.

In: Cardiology, Vol. 132, No. 3, 09.10.2015, p. 176-181.

Research output: Contribution to journalArticle

Golukhova, EZ, Grigorian, MV, Ryabinina, MN, Bulaeva, NI, Fortmann, S & Serebruany, VL 2015, 'Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up', Cardiology, vol. 132, no. 3, pp. 176-181. https://doi.org/10.1159/000435909
Golukhova EZ, Grigorian MV, Ryabinina MN, Bulaeva NI, Fortmann S, Serebruany VL. Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. Cardiology. 2015 Oct 9;132(3):176-181. https://doi.org/10.1159/000435909
Golukhova, Elena Z. ; Grigorian, Marina V. ; Ryabinina, Mariya N. ; Bulaeva, Naida I. ; Fortmann, Seth ; Serebruany, Victor L. / Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. In: Cardiology. 2015 ; Vol. 132, No. 3. pp. 176-181.
@article{a8eea02223dc47578e7f2b3c4833431d,
title = "Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up",
abstract = "Background: Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality. Therefore, predicting secondary vascular occlusions represents an unmet medical need. Objective: The aim of our study was to triage clinical and laboratory predictors of major adverse clinical events (MACE) following coronary stenting. Methods: This was a prospective, case-controlled, single-center study, which included 94 consecutive patients with documented coronary disease who underwent PCI with drug-eluting stent (DES) implantation. All patients received dual antiplatelet therapy with aspirin and clopidogrel. Numerous clinical characteristics and laboratory biomarkers were assessed before stenting and were correlated with poststenting MACE over the mean follow-up of 28 months. MACE included death, nonfatal myocardial infarction, target vessel revascularisation, stroke, stent thrombosis, angina recurrence and instent restenosis. Results: Twenty-three patients experienced MACE. Independent MACE predictors after PCI with DES implantation were antecedent diabetes mellitus (RR = 0.45; 95{\%} CI 0.20-0.97; p = 0.045), prior thrombolytic therapy (RR = 0.42; 95{\%} CI 0.27-0.83; p = 0.039), baseline plasminogen activator inhibitor-1 (PAI-1; p = 0.008) and plasma von Willebrand factor (vWF) activity (p = 0.007). Other clinical characteristics and laboratory indices showed no correlation with MACE. Conclusions: Background diabetes mellitus, prior thrombolytic therapy, PAI-1 and vWF prestenting activity may be useful for MACE prediction over 28 months of follow-up.",
keywords = "Coronary artery stenting, Dual antiplatelet therapy, Plasminogen activator inhibitor-1, Platelet aggregation, Stent restenosis, Stent thrombosis, von Willebrand factor",
author = "Golukhova, {Elena Z.} and Grigorian, {Marina V.} and Ryabinina, {Mariya N.} and Bulaeva, {Naida I.} and Seth Fortmann and Serebruany, {Victor L.}",
year = "2015",
month = "10",
day = "9",
doi = "10.1159/000435909",
language = "English (US)",
volume = "132",
pages = "176--181",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "3",

}

TY - JOUR

T1 - Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up

AU - Golukhova, Elena Z.

AU - Grigorian, Marina V.

AU - Ryabinina, Mariya N.

AU - Bulaeva, Naida I.

AU - Fortmann, Seth

AU - Serebruany, Victor L.

PY - 2015/10/9

Y1 - 2015/10/9

N2 - Background: Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality. Therefore, predicting secondary vascular occlusions represents an unmet medical need. Objective: The aim of our study was to triage clinical and laboratory predictors of major adverse clinical events (MACE) following coronary stenting. Methods: This was a prospective, case-controlled, single-center study, which included 94 consecutive patients with documented coronary disease who underwent PCI with drug-eluting stent (DES) implantation. All patients received dual antiplatelet therapy with aspirin and clopidogrel. Numerous clinical characteristics and laboratory biomarkers were assessed before stenting and were correlated with poststenting MACE over the mean follow-up of 28 months. MACE included death, nonfatal myocardial infarction, target vessel revascularisation, stroke, stent thrombosis, angina recurrence and instent restenosis. Results: Twenty-three patients experienced MACE. Independent MACE predictors after PCI with DES implantation were antecedent diabetes mellitus (RR = 0.45; 95% CI 0.20-0.97; p = 0.045), prior thrombolytic therapy (RR = 0.42; 95% CI 0.27-0.83; p = 0.039), baseline plasminogen activator inhibitor-1 (PAI-1; p = 0.008) and plasma von Willebrand factor (vWF) activity (p = 0.007). Other clinical characteristics and laboratory indices showed no correlation with MACE. Conclusions: Background diabetes mellitus, prior thrombolytic therapy, PAI-1 and vWF prestenting activity may be useful for MACE prediction over 28 months of follow-up.

AB - Background: Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality. Therefore, predicting secondary vascular occlusions represents an unmet medical need. Objective: The aim of our study was to triage clinical and laboratory predictors of major adverse clinical events (MACE) following coronary stenting. Methods: This was a prospective, case-controlled, single-center study, which included 94 consecutive patients with documented coronary disease who underwent PCI with drug-eluting stent (DES) implantation. All patients received dual antiplatelet therapy with aspirin and clopidogrel. Numerous clinical characteristics and laboratory biomarkers were assessed before stenting and were correlated with poststenting MACE over the mean follow-up of 28 months. MACE included death, nonfatal myocardial infarction, target vessel revascularisation, stroke, stent thrombosis, angina recurrence and instent restenosis. Results: Twenty-three patients experienced MACE. Independent MACE predictors after PCI with DES implantation were antecedent diabetes mellitus (RR = 0.45; 95% CI 0.20-0.97; p = 0.045), prior thrombolytic therapy (RR = 0.42; 95% CI 0.27-0.83; p = 0.039), baseline plasminogen activator inhibitor-1 (PAI-1; p = 0.008) and plasma von Willebrand factor (vWF) activity (p = 0.007). Other clinical characteristics and laboratory indices showed no correlation with MACE. Conclusions: Background diabetes mellitus, prior thrombolytic therapy, PAI-1 and vWF prestenting activity may be useful for MACE prediction over 28 months of follow-up.

KW - Coronary artery stenting

KW - Dual antiplatelet therapy

KW - Plasminogen activator inhibitor-1

KW - Platelet aggregation

KW - Stent restenosis

KW - Stent thrombosis

KW - von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=84939481445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939481445&partnerID=8YFLogxK

U2 - 10.1159/000435909

DO - 10.1159/000435909

M3 - Article

VL - 132

SP - 176

EP - 181

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 3

ER -